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Abstract
Swine influenza A viruses (IAV-S) found in North American pigs are diverse and the lack of
cross-protection among heterologous strains is a concern. The objective of this study was to
compare a commercial inactivated A/H1N1/pdm09 (pH1N1) vaccine and two novel subunit
vaccines, using IAV M2 ectodomain (M2e) epitopes as antigens, in a growing pig model.
Thirty-nine 2-week-old IAV negative pigs were randomly assigned to five groups and rooms.
At 3 weeks of age and again at 5 weeks of age, pigs were vaccinated intranasally with an
experimental subunit particle vaccine (NvParticle/M2e) or a subunit complex-based vaccine
(NvComplex/M2e) or intramuscularly with a commercial inactivated vaccine (Inact/pH1N1).
At 7 weeks of age, the pigs were challenged with pH1N1 virus or sham-inoculated. Nec-
ropsy was conducted 5 days post pH1N1 challenge (dpc). At the time of challenge one of
the Inact/pH1N1 pigs had seroconverted based on IAV nucleoprotein-based ELISA, Inact/
pH1N1 pigs had significantly higher pdm09H1N1 hemagglutination inhibition (HI) titers com-
pared to all other groups, and M2e-specific IgG responses were detected in the NvParticle/
M2e and the NvComplex/M2e pigs with significantly higher group means in the NvComplex/
M2e group compared to SHAMVAC-NEG pigs. After challenge, nasal IAV RNA shedding
was significantly reduced in Inact/pH1N1 pigs compared to all other pH1N1 infected groups
and this group also had reduced IAV RNA in oral fluids. The macroscopic lung lesions were
characterized by mild-to-severe, multifocal-to-diffuse, cranioventral dark purple consoli-
dated areas typical of IAV infection and were similar for NvParticle/M2e, NvComplex/M2e
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and SHAMVAC-IAV pigs. Lesions were significantly less severe in the SHAMVAC-NEG and
the Inact/pH1N1pigs. Under the conditions of this study, a commercial Inact/pH1N1 specific
vaccine effectively protected pigs against homologous challenge as evidenced by reduced
clinical signs, virus shedding in nasal secretions and oral fluids and reduced macroscopic
and microscopic lesions whereas intranasal vaccination with experimental M2e epitope-
based subunit vaccines did not. The results further highlight the importance using IAV-S
type specific vaccines in pigs.
Introduction
Influenza A virus (IAV), a genus within the family Orthomyxoviridae, is a negative sense, sin-
gle-stranded RNA virus. The IAV genome consists of eight segments that encode a minimum
of 10 viral proteins. The glycoproteins hemagglutinin and neuraminidase are located on the
surface of the virus and often used for characterization of IAV strains [1]. These glycoproteins
are responsible for viral entry and subsequent viral release from the infected cells, are highly
variable and are the major targets of the host humoral immune response [1].
Swine IAV (IAV-S) is considered one of the most important causes of acute respiratory dis-
eases in U.S. swine herds. Infection of pigs with IAV-S typically manifests as an acute, highly
contagious disease that often affects an entire herd in a short period of time [2]. The main clin-
ical signs of IAV-S infection are depression, fever, anorexia, coughing and dyspnea [2]. Mor-
tality can vary from 1–4%. In addition, IAV-S is considered a zoonotic pathogen and
transmission between pigs and humans occurs on a regular basis [3,4] making IAV-S an
important public health consideration. The populations of IAV found in North American pigs
are very diverse and include H3N2, H1N1 and H1N2 viruses with a more limited distribution
of other subtypes. During 2009, a worldwide influenza pandemic with a novel swine-derived
A/H1N1/pdm09 (pH1N1) occurred in humans [5] and the virus also re-entered the pig popu-
lation where it continues to spread. Commercial inactivated vaccines against pH1N1 are avail-
able to date for pigs and it has also been shown that vaccination of swine workers had a
beneficial effect on minimizing IAV-S transmission between farms [6].
Vaccination, while often used in U.S. pigs, is not always effective due to the heterogeneity of
circulating IAV-S strains. All of the licensed, commercial IAV-S vaccines currently available in
the U.S. contain inactivated virus or subunit virus particles. Influenza virus is cultivated in
eggs or cell culture and inactivated with chemical agents, such as formaldehyde or binary ethy-
lenimine for use in vaccines [7]. There is a need for novel and universal vaccine strategies capa-
ble of cross-protection against genetically different IAV-S strains.
Recently, two polyvalent vaccine platforms based on the norovirus (Nv) capsid protein have
been developed [8,9] and utilized for the development of a universal IAV-S vaccine [10,11].
The M2 protein is integrated into the viral envelope of IAV and its ion channel activity is
required for efficient viral uncoating during virus invasion of cells. The M2e epitope, which is
23 amino acid residues in length, is the extracellular moiety of the M2 protein. This epitope is
abundantly expressed on the surface of IAV-infected cells and M2e domains are highly con-
served among IAV strains, making it an attractive target for a universal vaccine [12,13]. The
protruding domain (P) particle platform is based on P particles which each contain 24 copies
of Nv P domains with three exposed loops on the outermost surface in which the M2e epitope
has been inserted [8]. The large complex-based platform is based on fusion of 2–3 dimeric/
oligomeric antigens that are fused into one molecule through recombinant DNA technology
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with large, higher order complexes assembling spontaneously through dimerization and/or
oligomerization of the homologous antigen [11,14]. Both P particle- (NvParticle/M2e) and
large complex-based (NvComplex/M2e) vaccines containing the M2e epitope have been pro-
duced in E. coli with high yield and high stability. Mouse experiments revealed that both vac-
cines were highly immunogenic and were able to fully protect vaccinated mice against IAV
lethal challenge using a mouse-adapted human IAV (H1N1, A/PR/8/34 [PR8] strain) [11,14].
The objective of this study was to determine the efficacy of a commercial inactivated
pH1N1 vaccine administered intramuscularly and two experimental M2e subunit vaccines
administered intranasally in protecting pigs from the effects of pH1N1 challenge.
Materials and methods
Ethical statement
The Iowa State University Institutional Animal Care and Use Committee approved this study
(Approval number 3-16-8220-S). The efforts to alleviate suffering in this study included
defined endpoints for each pig and independent veterinary supervision for the duration of the
project.
Pigs and experimental design
Thirty-nine 3-week-old pigs were obtained from an IAV-S-free herd and were randomly
assigned to five rooms with 7–8 pigs in each group (Fig 1). Water and feed were provided ad
libidum. Vaccination or sham-vaccination was done at 3 and 5 weeks of age followed by chal-
lenge or sham-challenge at 7 weeks of age. All pigs were euthanized 5 days post challenge
(dpc). Blood was collected in serum separator tubes (Fisher Scientific, Pittsburgh, Pennsylva-
nia, USA) weekly until challenge and at dpc 5. Blood tubes were centrifuged at 3000×g for 10
min at 4˚C and serum was stored at -80˚C until testing. Nasal swabs were collected individu-
ally from each pig on dpc 0, 1, 2, 3, 4 and 5 using polyester swabs and were stored in 5 ml plas-
tic tubes containing 1 ml of sterile saline solution at -80˚C until testing.
Clinical assessment
All pigs were weighed at vaccination 1 (dpc -28), at challenge (dpc 0) and at necropsy (dpc 5)
and the average daily weight gain was calculated. Rectal temperature, nasal discharge, cough
and respiratory scores were assessed every day starting on dpc 0 (Fig 1). Nasal discharge was
recorded as 0 = none, 1 = mild and 2 = severe and if present the location (left nostril, right nos-
tril, both), color (clear, yellow, white) and consistency (watery, mucoid) were also noted. The
cough score ranged from 0 = absent, 1 = single cough, and 2 = persisting cough, and respira-
tory scores ranged from 0 = normal to 6 = severe respiratory distress when at rest [15].
Vaccines and vaccination
Vaccine details are summarized in Table 1. The vaccine used for the NvParticle/M2e group
was a P particle-based vaccine [8,10] containing a pig IAV M2e epitope (SLLTEVETPIRNG
WECKCNDSSD) [16]. The vaccine used for the NvComplex/M2e group was an agglomerate
polymer-based (GST-P+) vaccine [11] containing a human IAV consensus M2e epitope
(SLLTEVETPIRNEWGCRCNDSSD) [8,17]. Both vaccines were expressed in E. coli. The two
M2e epitope sequences share 82% identity or 91% similarity. The vaccine used for the Inact/
pH1N1 group was a commercially available inactivated IAV-S vaccine purchased from MWI
Veterinary Supply (Boise, ID, USA).
Influenza A virus vaccination in the pig model
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All pigs in the NvParticle/M2e group, NvComplex/M2e group and Inact/pH1N1group
were vaccinated at dpc -28 and again at dpc -14. Pigs in the NvParticle/M2e and NvComplex/
M2e groups were vaccinated intranasally with 2 ml of the P-particle vaccine or the complex
vaccine, each containing 50 μg of protein vaccine by using a mucosal atomization device
(MAD300, American Medical; Green Bay, WI, USA). While in previous mouse studies no
adjuvants were used, in this study the vaccines were prepared by mixing 500 μl of the respec-
tive protein stock at a concentration of 1 mg/ml and 1.5 ml Polyinosinic-polycytidylic acid
Fig 1. Experimental design. Vaccinations and sham-vaccinations were done when the pigs were 3 weeks old and repeated at 5 weeks
of age. All pigs except the SHAMVAC-NEG group were challenged with IAV at 7 weeks of age. Necropsy was done at 5 days post
challenge.
https://doi.org/10.1371/journal.pone.0191739.g001
Table 1. Details on the vaccines or sham vaccines used in the different treatment groups.
Group Type Antigen Platform Vaccination route
NvParticle/M2e Subunit M2e epitope Nv P particle3 Intranasally
NvComplex/M2e Subunit M2e epitope Nv Complex4 Intranasally
Inact/pH1N1 Commercial inactivated1 Whole pH1N1 virus2 NA5 Intramuscularly
SHAMVAC-IAV Sham Saline NA Intramuscularly
SHAMVAC-NEG Sham Saline NA Intramuscularly
1 FluSure1 Pandemic (Zoetis).
2 A/California/04/2009 (pH1N1).
3 Nv = norovirus, P = protruding domain. Each P particle contains 24 copies of NvV P domains with three exposed loops on the outermost surface in which the M2e
epitope has been inserted.
4 Two to three dimeric/oligomeric antigens are fused into one molecule through recombinant DNA technology. The large, higher-order complexes of the fused antigens
assemble spontaneously through dimerization and/or oligomerization of the homologous antigen.
5 Not applicable.
https://doi.org/10.1371/journal.pone.0191739.t001
Influenza A virus vaccination in the pig model
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potassium salt adjuvant (PolyI:C; Sigma-Aldrich) at a concentration of 156 μg/ml shortly
before administration to the pigs. Previously, PolyI-C adjuvant has been shown to enhance
immune responses against IAV after intranasal administration [18]. Pigs in the Inact/
pH1N1group were vaccinated with 2 ml of FluSure1 Pandemic (Zoetis; serial numbers
149390 and 120823) intramuscularly into the neck area after rehydration of the freeze-dried
vaccine as recommended by the manufacturer.
pH1N1 challenge
The pH1N1 isolate A/California/04/2009 was selected for challenge at dpc 0. The pigs were
anesthetized with an intramuscular administered cocktail of ketamine (8 mg/kg of body
weight), xylazine (4 mg/kg), and Telazol (6 mg/kg) as described [19] and challenged intratra-
cheally (2 ml) and intranasally (1 ml) with the pdm09H1N1 strain at a dose of 2 × 105 TCID50.
Pigs in the SHAMVAC-NEG group were challenged by the same routes using similar amounts
of saline.
Serology
To assess the antibody response against IAV-S in serum samples, a commercial IAV-S block-
ing ELISA (IDEXX Swine Influenza Virus Ab Test; IDEXX Inc., Westbrook, MA, USA) was
used according to the manufacturer’s instructions. This ELISA detects antibodies directed
against the IAV nucleoprotein (NP). A sample-to-negative control (S/N) ratio less than 0.6
was considered positive. In addition to serum, this assay was also used on oral fluids and
bronchoalveolar lavage (BAL) fluid with the following modifications: each plate was loaded
with 200 μl undiluted OF or BAL fluid and incubated for 16 h at 21˚C [20]. Serum, OF and
BAL fluid reactions were measured as optical density (OD) at a wavelength of 650 nm using an
ELISA plate reader. Sample-to-negative (S/N) ratios were calculated as described by the manu-
facturer, with S/N ratios of0.60 considered antibody positive. For the OF test interpretation,
in addition to the S/N ratio cut-off of0.60 as suggested for serum samples by the manufac-
turer, results were also obtained and evaluated using a S/N ratio cut-off of0.65 as suggested
by a previous study [20]. In addition, serum samples collected at challenge (dpc 0) and nec-
ropsy (dpc 5) were also tested by a hemagglutinin inhibition (HI) assay. In brief, sera were heat
inactivated at 56˚C for 30 min to remove nonspecific hemagglutinin inhibitors and natural
serum agglutinins, according to standard techniques used at the Iowa State University Veteri-
nary Diagnostic Laboratory. The HI assay was performed using pH1N1antigen and turkey red
blood cells.
Demonstration of M2e specific antibodies
An in-house M2e ELISA to detect pig specific antibodies was performed as described elsewhere
[10] and with modifications tested on lavage samples collected at necropsy for presence of
anti-M2e IgA levels and on serum samples collected at challenge for anti-M2e IgG levels.
Briefly, two synthetic M2e peptides, SLLTEVETPIRNGWECKCNDSSD for the NvParticle/M2e
vaccine and SLLTEVETPIRNEWGCRCNDSSDfor the NvComplex/M2e vaccine (3 μg/ml,
Ohio peptide, USA), were used as detection antigens for M2e specific antibodies. Sera and
lung washes were initially diluted to 1:25 (for lung washes) or 1:100 (for sera) and then 2-fold
serial dilutions were made in 5% non-fat dry milk in PBS (pH 7.4) for the end-point titer deter-
mination. The M2e peptides were coated on 96 well microtiter plates (Nunc MaxiSorp1,
USA) (200 ng/well) at 4˚C for overnight. Before detection, the coated plates were blocked with
200 μl of 5% non-fat dry milk in PBS for 1 h at 37˚C. After washing, diluted sera or lung washes
(100 μl) were added to the plates for 1 h at 37˚C. The bound antibody was detected by the HRP
Influenza A virus vaccination in the pig model
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(horse reddish peroxidase)-conjugated goat anti-Pig IgG (for serum IgG) and HRP-conjugated
goat anti-Pig IgA (for IgA in the lung wash) as secondary antibodies (Abcam, Cambridge, MA,
USA). Antigen-specific antibody titers were defined as the endpoint dilution with a cut off sig-
nal intensity of 0.2.
Serum samples collected at the day of challenge were also characterized by western blot uti-
lizing lysates from MDCK cells that had been infected with either PR8 virus or a PR8 7:1 reas-
sortant with segment 7 from the pH1N1 strain A/California/ 07/2009 at an MOI of 5 as targets
[21]. Cell lysates were harvested 24 hours post infection and run on SDS-PAGE gradient gels
(4–20%) for separation of proteins before transferring to nitrocellulose membranes. Mem-
branes were probed with a rabbit polyclonal anti-NP serum [21] to confirm infection and
mouse monoclonal antibody 14C2 (Abcam) for detection of the PR8 M2 protein followed by
rabbit and mouse secondary antibodies (1:20,000) as appropriate. Serum samples were tested
using the Mini Protean II multiscreen (Biorad) with secondary swine antibodies (1:10,000).
Membranes were developed by chemiluminescence using ECL Plus (Amersham).
Detection and quantification of IAV-S specific nucleic acids and virus
titration
Total nucleic acids were extracted from nasal swabs, oral fluids and bronchoalveolar lavage
(BAL) samples using a MagMAX-96 viral isolation kit (Applied Biosystems, Life Technologies,
Carlsbad, CA, USA) on a KingFisher™ Flex platform (ThermoFisher Scientific, Pittsburgh, PA,
USA). Appropriate negative and positive controls were included in each extraction run. A
quantitative reverse transcriptase (RT) real-time PCR based on the N1 gene specific for pH1
NA was performed on the RNA extracts. In addition, selected samples were also tested by a
real-time PCR based on the M gene [22]. Virus titration was done on nasal swabs and BAL flu-
ids as described [23] and titers were presented as TCID50 per ml.
Necropsy and gross lung lesions
On dpc 5, all pigs were euthanized by intravenous pentobarbital overdose (FATAL-PLUS1,
Vortech Pharmaceuticals LTD, Dearborn, MI, USA) and necropsied. The percentage of lung
surface affected by visible lesions was assessed by a pathologist blinded to the pig treatment sta-
tus using an established protocol [15]. BAL fluids were collected from each pig using minimal
essential medium (MEM, Fisher Scientific). In addition, lung sections from the right cranial,
right middle and accessory lung lobes and a section of distal trachea were collected. The sections
were immersed in 10% neutral-buffered formalin and routinely processed for histopathology.
Histopathology and immunohistochemistry
Tissue sections were fixed and microscopic lung lesions were assessed by a veterinary patholo-
gist blinded to treatment status and scored for presence and degree of tracheitis, tracheal epi-
thelial flattening or attenuation, bronchi and bronchiolar epithelial changes and
peribronchiolar lymphocytic cuffing ranging from 0 = none to 4 = severe as described [23].
Presence and amount of IAV-S specific antigen in tissue sections were assessed by immunohis-
tochemistry (IHC) as described [24,25]. The IAV antigen scores ranged from 0 = absent to
4 = abundant diffuse signals. Scoring was done blinded to the treatment status.
Statistics
RNA genomic copies in nasal swabs and HI titers were log transformed prior to analysis. A
one-way analysis of variance (ANOVA) was utilized to detect significant differences among
Influenza A virus vaccination in the pig model
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treatment groups and pair-wise comparison were performed by least significant difference.
The rejection level for the null hypothesis was P< 0.05. Pairwise testing was performed using
Tukey-Kramer adjustment to identify different groups. Non-repeated measures were assessed
using nonparametric Kruskal-Wallis ANOVA. When group variances were different, pair-
wise comparisons were performed using the Wilcoxon rank sum test. Differences in incidence
were evaluated by using Fisher’s exact test.
Results
Clinical disease
No clinical signs of respiratory disease were observed in any of the pigs prior to challenge or in
the SHAMVAC-NEG pigs for the duration of the experiment. The average daily gain in
grams ± SEM from the time of challenge until necropsy was 279.7±59.2 for the SHAMVAC--
NEG pigs, 224.0±36.8 for the NvComplex/M2e pigs, 234.4±87.7 for the NvParticle/M2e pigs,
172.0±23.3 for the Inact/pH1N1 pigs and 207.9±54.6 for the SHAMVAC-IAV pigs which was
not significantly different (P = 0.715). In IAV infected pigs, coughing was first observed in
SHAMVAC-IAV and NvComplex/M2e pigs by dpc 2 (Fig 2A) in NvParticle/M2e pigs by dpc
3 and in Inact/pH1N1by dpc 5. Overall, 5/7 NvParticle/M2e pigs, 4/8 NvComplex/M2e pigs,
2/8 Inact/pH1N1pigs and 5/8 SHAMVAC-IAV pigs were observed coughing for 1–3 consecu-
tive days and the average number of days with coughing was significantly higher for SHAM-
VAC-IAV pigs (1.5±0.4) compared to SHAMVAC-NEG pigs (0). Nasal discharge was
observed in 4/7 NvParticle/M2e pigs, 5/8 NvComplex/M2e pigs, 2/8 Inact/pH1N1pigs and 8/8
SHAMVAC-IAV pigs for 1–3 days. The average number of days a pig was scored with a respi-
ratory score of 1 or greater was 2.0±0.7 for NvParticle/M2e pigs, 1.8±0.5 for NvComplex/M2e
pigs, 1.4±0.3 for Inact/pH1N1pigs, 3.3±0.4 for SHAMVAC-IAV pigs and 0.3±0.2 for SHAM-
VAC-NEG pigs. The group mean respiratory scores over time are summarized in Fig 2B and
the mean group rectal temperatures are presented in Fig 2C. For the purpose of this study,
fever was defined as a rectal temperature greater than 40.5˚C. Two of 7 NvParticle/M2e pigs,
2/8 NvComplex/M2e pigs and 3/8 SHAMVAC-IAV pigs had fevers by dpc 4 and dpc 5 lasting
1–2 days without group mean differences among all groups.
Serology
SHAMVAC-NEG pigs remained seronegative for IAV NP throughout the duration of the
study (Table 2). At the dpc 0, 1/7 NvParticle/M2e and 1/8 Inact/pH1N1pigs had S/N ratios less
than 0.6 and were considered positive. By dpc 5, the group mean Inact/pH1N1 ELISA value
was significantly lower compared to all other groups which is indicative of seroconversion and
7/8 Inact/pH1N1 pigs were considered NP-seropositive based on the assay cutoff. In BAL
fluid, 1/8 SHAMVAC-IAV pigs were ELISA positive (Table 2). Using a pH1N1 specific HI
assay, SHAMVAC-NEG pigs remained seronegative for pH1N1 surface antigens throughout
the duration of the trial (Table 2). Inact/pH1N1 pigs had significantly higher pH1N1 HI titers
compared to all other groups by dpc 0 and 5. An in house assay was used to test for specific
M2e IgA (BAL fluid) and IgG (serum samples) antibodies and a western blot assay was used to
test for antibodies against the M2e PR8/Cal07 epitopes in serum samples. All samples were
negative by the M2e IgA assay but IgG M2e specific antibody responses were detected in the
NvParticle/M2e and the NvComplex/M2e pigs. Specifically, titers as high as 1:12800 were
observed in1/7 NvParticle/M2e pigs and in 2/8 NvComplex/M2e pigs at the time of challenge.
Moreover, the log transformed group mean in the NvComplex/M2e group was significantly
higher compared to that of the SHAMVAC-NEG pigs (3.8±0.2 versus 3.5±0.1).
Influenza A virus vaccination in the pig model
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Fig 2. Mean group clinical assessment on the day of IAV challenge and on day post challenge (dpc) 1–5. A. Presence of cough ranging from 0 = absent to
2 = persisting cough. B. Respiratory score ranging from 0 = normal to 6 = severe respiratory distress when at rest. C. Rectal temperature. Different superscripts (A,B) on
certain dpc indicate significantly (P< 0.05) different group means.
https://doi.org/10.1371/journal.pone.0191739.g002
Table 2. Antibody responses as determined by a commercial blocking ELISA or a pdm09H1N1 specific HI assay on serum samples or bronchoalveolar lavage (BAL)
fluid in the different treatment groups at -28, 0, and 5 days after pdm09H1N1 challenge.
Group -28 (Serum) 0 (Serum) 5 (Serum) 5 (BAL fluid)
NP ELISA1 NP ELISA1 pH1N1HI2 NP ELISA1 pH1N1 HI2 NP ELISA1
NvParticle/M2e 0/7 (0.96±0.02)A,3 1/7 (0.94±0.06)AB 0/7 (3.1±1.9)A 0/7 (0.80±0.02)A 0/7 (3.8±1.5)A 0/7 (1.20±0.13)A
NvComplex/M2e 0/8 (1.00±0.01)A 0/8 (0.93±0.02)AB 0/8 (1.8±2.0)A 0/8 (0.83±0.03)A 0/8 (3.4±1.9)A 0/8 (1.29±0.12)A
Inact/pH1N1 0/8 (0.95±0.02)A 1/8 (0.74±0.08)A 8/8 (8.3±1.1)B 7/8 (0.42±0.05)B 8/8 (8.5±1.0)B 0/8 (0.88±0.05)A
SHAMVAC-IAV 0/8 (0.96±0.02)A 0/8 (0.94±0.04)AB 0/8 (1.5±1.8)A 0/8 (0.84±0.03)A 0/8 (4.2±1.5)A 1/8 (1.10±0.17)A
SHAMVAC-NEG 0/8 (0.94±0.01)A 0/8 (0.95±0.02)B 0/8 (2.2±2.0)A 0/8 (0.94±0.02)A 0/8 (2.1±1.8)A 0/8 (0.94±0.05)A
1 Positive pigs/total number of pigs per group (mean group sample-to-negative (S/N) nucleoprotein blocking ELISA ratios ± SEM). An S/N ratio less than 0.6 was
considered positive.
2 Pigs with an HI titer > 40/total number of pigs per group [26] (mean log2 transformed pH1N1 HI titers ± SEM).
3 Different superscripts indicate significantly (P< 0.05) different group mean S/N values or HI titers at a dpc.
https://doi.org/10.1371/journal.pone.0191739.t002
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Presence of IAV RNA
The amounts of IAV RNA in individual pigs are summarized for each group in S1 Fig. The
group mean log10 IAV RNA levels in nasal swabs and BAL fluid are summarized in Fig 3A.
IAV RNA was not detected in any of the SHAMVAC-NEG group samples and by dpc 2 mean
group IAV RNA levels in nasal swabs and also in BAL fluids were significantly lower in Inact/
pH1N1pigs compared to all other IAV infected groups. The group mean log10 IAV RNA levels
in oral fluids are summarized in Fig 3B. There was a similar trend as seen with nasal swabs
with Inact/pH1N1pigs having lower levels of IAV RNA in oral fluids compared to all other
IAV infected pigs.
Virus levels in nasal secretions and in lungs
In nasal swabs collected daily after challenge, virus was isolated from NvParticle/M2e pigs (5/7
on dpc 1, 0/7 on dpc 2, 3/7 on dpc 3, 2/7 on dpc 4 and on dpc 5), NvComplex/M2e pigs (5/8
on dpc 1, 5/8 on dpc 2, 2/8 on dpc 3, 2/8 on dpc 4 and 1/8 on dpc 4) and the SHAMVAC-IAV
pigs (7/8 on dpc 1, 7/8 on dpc 2, 2/8 on dpc 3, 5/8 on dpc 4 and 4/8 on dpc 5) at certain days.
At necropsy, 85.7% (6/7) of the NvParticle/M2e pigs, 50% (4/8) of the NvComplex/M2e pigs
and 62.5% (5/8) of the SHAMVAC-IAV pigs had viable IAV virus in BAL fluids. All Inact/
pH1N1pigs were negative for infectious IAV in nasal swabs and BAL fluids.
Lesions and IAV antigen in tissue sections
Macroscopic lung lesions associated with IAV infection were characterized by mild-to-severe,
multifocal-to-diffuse, cranioventral, dark-purple consolidated areas (Fig 4); however, lesions
were essentially absent in Inact/pH1N1pigs. Microscopically there was necrosis and flattening
of the epithelium lining airways associated with accumulation of inflammatory cells in the
lung and distal trachea. These lesions were almost always associated with large amounts of
IAV antigen as determined by IHC stains (Table 3).
Fig 3. Mean group log10 IAV RNA genomic copies ±SEM. A. Nasal swabs were collected at day post challenge (dpc) 1–5 and bronchoalveolar lavage (BAL) fluid was
collected on dpc 5. Different superscripts (A,B) on certain dpc indicate significantly (P< 0.05) different group means. B. Pen/group based oral fluid samples collected at
dpc 1–5.
https://doi.org/10.1371/journal.pone.0191739.g003
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Discussion
In this study, two novel experimental and broadly-reactive subunit IAV vaccines previously
tested in mice [8–11] were compared to a commercially available conventional inactivated
type-specific IAV vaccine in the pig model. In the past, experimental work carried out in mice
has not translated well to humans limiting the usefulness of this model. The use of pigs models
that are more similar to humans may be more appropriate [27].
Pigs vaccinated with the commercial inactivated type-specific vaccine were protected
against pH1N1 challenge based on reduced shedding of IAV RNA in nasal secretions and oral
fluids and reduced macroscopic and microscopic lesions; however, pigs vaccinated with the
experimental broadly-reactive subunit vaccines were not, and developed clinical disease and
severe macroscopic and microscopic lung lesions similar to the non-vaccinated SHAMVA-
C-IAV pigs.
Fig 4. Macroscopic lung lesions at 5 days post IAV challenge. A. SHAMVAC-NEG pig 229: There are no visible lung lesions present (Score: 0). B. SHAMVAC-IAV
pig 244: Dorsoventral there is diffuse severe dark purple consolidation present (Score: 30.1). C. NvParticle/M2e pig 239: Dorsoventral there is diffuse severe dark
purple consolidation present (Score: 33.5). D. NvComplex/M2e pig 232: Dorsoventral there is diffuse severe dark purple consolidation present (Score: 31.1). E. Inact/
pH1N1pig 234: There are no visible lung lesions present (Score: 0).
https://doi.org/10.1371/journal.pone.0191739.g004
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Having access to a broadly reactive “universal” IAV vaccine would be a great asset to pig
producers. Universal influenza vaccines have been reported previously, including self-assem-
bling protein nanoparticles displaying M2e and Helix C with incorporation of TLR5 agonist
flagellin, which has been shown to protect mice from lethal IAV challenge and also induced
high levels of antibodies in chickens [28]. A novel M2e-tetra-branched multiple antigenic pep-
tide based vaccine was evaluated in the mouse model and shown to be effective in protecting
mice against heterologous strains [29]. Baculovirus constructs expressing HA fused to swine
IgG2a Fc, displayed in a FeLV gag VLP, or displayed in the baculoviral envelope were gener-
ated and used to vaccinate pigs which elicited robust HI titers in serum and reduced lung
lesions and prevalence of virus after challenge [30]. Previously, the same subunit vaccines
tested in pigs in this study were used in the mouse model by vaccinating mice three times
intranasally at 2-week intervals and using the mouse adapted H1N1 PR8 strain. The results
demonstrated that the polyvalent GST-Nv P−-M2e vaccine fully protected mice against lethal
challenge [14]. Similar results were also obtained with a GST-Nv P+-M2e polymer vaccine
[11]. Despite being efficacious in mice using certain models, the vaccines failed to protect pigs
in this study. This reinforces that findings in the murine model may not be predictive of
responses in other animal species [31,32]. In addition, comparative mapping of anti-M2e anti-
bodies obtained from different species revealed that one epitope was exclusively recognized by
antibodies generated in rabbits while another epitope was only recognized by mice and chick-
ens indicating differences in species recognition [33].
The previously observed protection of the two subunit vaccines in mouse trials and the lack
of protection in this pig study potentially indicate differences in immune responses between
species. The structural diversity and the abundance and distribution of nasal cavity-associated
lymphoid tissues in both species may explain some of these differences [27,34,35]. Differences
in immune responses were observed when comparing inbred (BALB/c, C57BL/6, C3H and
BALB/cxC57BL/6) and outbred (CD1/ICR and Swiss Webster) mouse strains, since the second
group exhibited poor anti-M2e Ab levels [36]. Another factor that may have influenced the
immune response is the immunization route used herein. Most commercial pig vaccines avail-
able today are applied via the intramuscular route but it is suspected that, especially for respira-
tory infection, the intranasal vaccination would be beneficial. Therefore, the experimental M2e
vaccines used in this study were given intranasally. Previous studies comparing intranasal ver-
sus subcutaneous administration routes in chickens and mice showed that subcutaneous
Table 3. Mean group macroscopic lung lesions (percentage of the lung surface affected by lesions) and prevalence and group mean microscopic lung lesions and
IAV antigen as determined by immunohistochemical stains 5 days after pdm09H1N1 challenge.
Group Macroscopic lung
lesions
Microscopic lung lesions1 and IAV antigen Microscopic tracheal lesions1 and IAV antigen
Peribronchiolar cuffing Epithelial
necrosis
Lung IHC2 Tracheal epithelial
flattening
Tracheitis Trachea IHC2
NvParticle/M2e 15.4±3.7A,3 6/7 (1.6±0.3)A 7/7 (2.1±0.2)A 7/7 (2.0
±0.3)A
3/7 (0.7±0.4)A 5/7 (1.0
±0.3)A
3/7 (0.6
±0.3)A
NvComplex/M2e 14.3±3.7A 8/8 (2.6±0.4)B 8/8 (2.9±0.3)A 8/8 (2.8
±0.3)A
5/8 (1.3±0.4)A 7/8 (1.3
±0.4)A
8/8 (1.6
±0.3)A
Inact/pH1N1 0.1±0.1B 1/8 (0.1±0.1)C 0/8 (0)B 0/8 (0)B 0/8 (0)B 0/8 (0)B 0/8 (0)B
SHAMVAC-IAV 11.8±3.2A 8/8 (1.8±0.3)AB 8/8 (2.3±0.3)A 8/8 (2.8
±0.3)A
3/8 (1.0±0.3)A 5/8 (1.0
±0.3)A
5/8 (0.6
±0.2)A
SHAMVAC-NEG 0.1±0.0B 0/8 (0.1±0.1)C 0/8 (0)B 0/8 (0)B 0/8 (0)B 0/8 (0)B 0/8 (0)B
1 Score range from 0 = normal to 4 = severe.
2 Score range from 0 = not present to 4 = abundant.
3 Different superscripts indicate significantly (P< 0.05) different group mean values.
https://doi.org/10.1371/journal.pone.0191739.t003
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immunization induced significantly higher Ab levels in the serum compared to intranasal
[36,37] but we speculate that local mucosal protection against IAV is perhaps most important
compared to systemic protection. Future studies need to directly compare both administration
routes using the same products.
In addition, several factors regarding the design and application of the two subunit vaccines
may also have contributed to the failure of protection observed in pigs in this study: (1) Unlike
the inactivated whole pH1N1 virus-based Inact/pH1N1vaccine that should contain all original
IAV epitopes, the 23 amino acid-M2e epitope of the two subunit vaccines represent only a
small fraction of the IAV proteome. Hence, Inact/pH1N1 can elicit complex immune
responses to inhibit various steps of IAV infection, while the subunit vaccines in this study did
not elicit any detectable M2e-specific immune response. Previously it was found that M2e-
based vaccines confer relatively weak protection mediated via non-neutralizing immune
mechanisms compared to an inactivated IAV vaccine in mice [38]. Therefore, it may be under-
standable that the Inact/pH1N1vaccine exhibited much higher protection than the two subunit
vaccines; however, studies comparing the Inact/pH1N1 vaccine to the experimental M2e vac-
cines in the mouse model are lacking. (2) Due to its small size, the M2e epitope constitutes
only a small portion of the subunit vaccines, accounting for 7% and 4% of the NvParticle/M2e
and the NvComplex/M2e total protein, respectively. As a result, higher vaccine dose and dos-
age than the currently studied ones may be required to induce a higher M2e-specific immune
response. In previous trials, 15–30 μg of the subunit vaccines were used to immunize mice
three times to show protection [10,11,14] and 50 μg of the same subunit vaccines for two
immunizations may not have been sufficient to elicit protective immunity in the current pig
study. Thus, future studies with higher doses of the subunit vaccine are necessary. (3) BLAST
searches indicated that both M2e vaccine sequences used in this study match numerous M2e
sequences in pig IAV strains recovered from the U.S. and other countries. For the particular
pH1N1 challenge virus used in this study, both vaccines have a change on position 10
(Thr!Ile), and on positions 12 and 19 (Ser!Asn). In addition, the NvParticle vaccines has a
change on position 13 (Glu!Gly) and on position 17 (Ala!Lys), while the NvComplex vac-
cine has a change on position 15 (Glu!Gly). While the M2e epitope has been considered to
be very conserved posing an ideal universal IAV vaccine target [12,13], recognition of epitopes
could have been affected by changes in amino-acid side chain polarity, as occurred with
Thr!Ile on position 10 (both vaccines), and Glu!Gly on positions 13 (NvParticle vaccine)
and 15 (NvComplex vaccine), due to conformation of the resulting protein. However, this
needs to be further explored.
When tested with a commercial IAV NP-protein based blocking ELISA, most pigs in this
study remained negative for IAV specific antibodies. Pigs vaccinated with experimental
M2-based subunit vaccines were not expected to react with this assay since antibody directed
against the NP protein do not cross react with those against the M2 protein. However, even in
the Inact/pH1N1group only 1/8 pigs had a detectable response by dpc 0. Previously it has been
determined that, while vaccination affected the S/N antibody response, data did not support
the use of the NP ELISA for monitoring IAV vaccination compliance or for differentiating
between IAV-infected animals and IAV-infected and vaccinated animals [26]. Because of this,
an HI assay specific for subtype A/H1N1/pdm09 was also used. At challenge, all Inact/
pH1N1pigs had titers of 80 or greater whereas in all other groups titers were between 0 and 20.
This further confirms that all Inact/pH1N1pigs mounted a detectable immune response
against pH1N1 by the time of challenge. Mucosal immunity specific for M2e was measured by
IgA ELISA on lung lavage fluid collected at necropsy. However, none of the pigs had a detect-
able response. Nevertheless, results obtained with an IgG M2e ELISA on serum collected at
challenge indicated a weak but detectable M2e-specific IgG antibody response in the
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NvParticle/M2e and the NvComplex/M2e pigs with significantly higher group means in the
NvComplex/M2e pigs compared to the SHAMVAC-NEG pigs.
Conclusions
Under the study conditions, pigs vaccinated with the commercial inactivated vaccine were
protected against pH1N1 challenge based on reduced shedding of IAV RNA in nasal secre-
tions and oral fluids and reduced macroscopic and microscopic lesions. Pigs vaccinated with
the experimental subunit vaccines were not protected. Vaccine genetic makeup, dose, protein
concentration and administration route need to be further investigated and better adjusted
from usage in mice to usage in pigs.
Supporting information
S1 Fig. Individual pig log10 IAV RNA genomic copies in each group. Nasal swabs were col-
lected at day post challenge (dpc) 1–5 and bronchoalveolar lavage (BAL) fluid was collected on
dpc 5.
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